BEHANDLUNG VON MIGRÄNE

Patent europeic · EP3955933 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3955933
Numer da la dumonda
EP20722147
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
07-04-2020
Publitgà
23-02-2022
Concedì
29-11-2023
La protecziun finescha il pli tard
06-04-2040
Proxima taxa annuala scadenta
30-04-2027
Classas IPC
A61K 31/58 (2006.01)
A61P 29/00 (2006.01)
Prioritad
US 201962833994 P 15.04.2019
Dumonda PCT
PCT/US2020/027008 07.04.2020
Publicaziun PCT
WO2020/214452 22.10.2020
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 27-05-2026

    Midada

    Published in Swissreg on 27.05.2026

  2. 01-05-2025

    Midada

    Published in Swissreg on 01.05.2025

  3. 09-10-2024

    Midada

    Published in Swissreg on 09.10.2024

  4. 01-05-2024

    Midada

    Published in Swissreg on 01.05.2024

  5. 15-02-2024

    Represchentant inscrit

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 15.02.2024

  6. 29-11-2023

    Concedì

    Published in Swissreg on 29.11.2023

Partidas

Possessur

VistaGen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

343 Allerton Avenue, South San Francisco, CA 94080, US

Represchentant

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventur

MONTI, Louis

Mountain View, CA 94040, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.